弥漫性胶质瘤患者肿瘤相关神经认知功能障碍:抗肿瘤治疗前神经认知功能的系统综述
该系统综述检索PubMed和Embase(1995年至2016年11月),纳入23项抗肿瘤治疗前评估神经认知功能(NCF)的胶质瘤研究。组水平分析中13/14项研究(92.9%)显示NCF下降;个体水平任何域受损比例为62.6%(中位数,四分位距31.0-79.0);高级别胶质瘤较低级别胶质瘤认知受损更常见(OR 2.50;95%CI 1.71-3.66)。
要点
- 治疗前胶质瘤患者任何认知域受损比例为62.6%(中位数,四分位距31.0-79.0)。
- 组水平分析中13/14项研究(92.9%)报告NCF较常模或匹配对照下降。
- 高级别胶质瘤较低级别胶质瘤认知受损更常见(OR 2.50;95%CI 1.71-3.66)。
核心结论
- 大多数未治疗胶质瘤患者存在认知受损,提示神经认知功能障碍与肿瘤相关。
- 治疗前NCF文献以小规模研究为主,患者选择异质性强,偏倚风险高。
研究设计与样本
- 系统综述,按PRISMA-P方案检索PubMed和Embase(1995年至2016年11月)。
- 纳入23项评估胶质瘤患者抗肿瘤治疗前NCF的研究。
- 多数研究为小样本观察性前瞻性队列研究;11项(47.5%)研究根据肿瘤位置选择患者。
主要发现
- 组水平分析纳入14项研究,其中13项(92.9%)发现NCF较常模或匹配对照下降。
- 个体水平分析纳入15项研究,任何域NCF受损比例为62.6%(中位数;四分位距31.0-79.0)。
- 高级别胶质瘤较低级别胶质瘤认知受损更常见(OR 2.50;95%CI 1.71-3.66)。
局限性
- 文献以小规模研究为主。
- 患者选择异质性强,导致偏倚风险高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Deficits in neurocognitive functioning (NCF) frequently occur in glioma patients. Both treatment and the tumor itself contribute to these deficits. Data about the role of the tumor are scarce, because NCF has mostly been studied postoperatively. We aimed to summarize data on pre-treatment NCF in glioma patients and to determine the overall and domain-specific prevalence of neurocognitive dysfunction. We searched PubMed and Embase according to PRISMA-P protocol for studies that evaluated pre-treatment NCF in glioma patients (1995-November 2016) and extracted information about NCF. We performed analysis of data for two main outcome measures; mean cognitive functioning of the study sample (at group level) and the percentage of impaired patients (at individual level). We included 23 studies. Most studies were small observational prospective cohort studies. In 11 (47.5%) studies, patient selection was based on tumor location. NCF was analyzed at the group level in 14 studies, of which 13 (92.9%) found decreased NCF at group level, compared to normative data or matched controls. The proportion of individuals with decreased NCF was reported in 15 studies. NCF was impaired (in any domain) in 62.6% of the individuals (median; interquartile range 31.0-79.0). Cognitive impairments were more common in patients with high-grade glioma than with low-grade glioma (OR 2.50; 95% CI 1.71-3.66). Cognitive impairment occurs in the majority of treatment-naive glioma patients, suggesting that neurocognitive dysfunction is related to the tumor. However, the literature about pre-treatment NCF in glioma patients is characterized by small-scale studies and strong heterogeneity in patient selection, resulting in high risk of bias.
引用
- van Kessel E, Baumfalk AE, van Zandvoort MJE, et al. Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a systematic review of neurocognitive functioning prior to anti-tumor treatment. J Neurooncol. 2017. PMID: 28567586. doi:10.1007/s11060-017-2503-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。